Oncology indications increasingly use predictive biomarkers to guide prescribing of costly therapies. However, uptake of targeted therapies in Mexico and Argentina is highly dependent on their…
Last Updated 1 October 2014 The market for Alzheimer’s disease (AD) pharmacotherapies continues to offer compelling commercial opportunities driven by considerable unmet need. The AD population…
Benlysta (GlaxoSmithKline) is not only the first drug approved for systemic lupus erythematosus (SLE) in more than 50 years, but also the first biologic approved for the indication. However, uptake…
Last Updated 29 September 2014 Treatment options for Crohn’s disease (CD) include conventional, largely generic small molecules and more-potent biological agents, including tumor necrosis…
The financial burden of providing healthcare and the rising cost of the most innovative medicines have pressured government healthcare budgets and highlight the need for payers to operate under a…
The asthma market has historically been one of the most lucrative drug markets in the pharmaceutical industry owing to a large and growing patient population. However, generic and/or branded-…
Oncology is increasingly moving toward a personalized treatment approach, enlisting predictive biomarkers to guide therapy choice. This trend is already being felt in indications as varied as…
The use of biomarkers and personalized medicine is at a very early stage in asthma. Although most asthma patients can obtain disease control through treatment with available therapies, there…
Gastric cancer is the fourth-most common malignancy in terms of incidence and is the third-most common cause of cancer-related death worldwide. Japan has the highest incidence of gastric cancer…
South Korea and Taiwan have the most advanced healthcare systems among Asian countries, and both operate a universal health insurance program that covers inpatient and outpatient services as well…
Last Updated 12 September 2014 The type 2 diabetes therapy market will rapidly expand over our 2013-2023 study period, fueled by the disease’s increasing prevalence and a high unmet need for…
Crohn’s disease (CD) and ulcerative colitis (UC) are two gastrointestinal autoimmune/inflammatory indications that commonly feature treatment with biological therapies. The U.S. CD market…
Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable,…
In 2013, global sales of ethical oncology drugs exceeded $92 million, and sales are expected to exceed $120 million in 2020, far more than the drug revenues of any other therapy area. Thus,…
The TreatmentTrends: Rheumatoid Arthritis 2014 (EU) report explores the treatment dynamics among more than 200 French, German, Italian, Spanish, and UK rheumatologists through comprehensive primary…